Journals / Gülhane Tıp Dergisi / 2007 / Cilt: 49 - Sayı: 1

The efficacy and the safety of the NMP22 test in the follow-up of urinary bladder transitional cell carcinoma after transurethral resection

Mesane transizyonel hücreli karsinomunun transüretral rezeksiyon sonrası takibinde NMP22 testinin etkinliği ve güvenilirliği

Pages
14–20
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Although the sensitivity and negative predictive value of NMP22 test were significantly higher than those of urine cytology in bladder transitional cell carcinomas, especially with low grade and stage, it should be evaluated as a complemantary test to cytology rather than taking place of it as an assistant method to cystoscopy since it does not have sufficient specificity.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:This study has been prepared to evaluate the efficacy of NMP22 test in the followup of recurrent bladder transitional cell carcinoma and to compare it with urine cytology used to assist to cystoscopy.
📊
Key Findings & Data:Urine samples voided prior to cystoscopic examination were collected from 94 patients who were in the follow-up program for superficial bladder cancer, and stabilized in the NMP22 urine collection kit.
💡
Conclusion & Impact:Although the sensitivity and negative predictive value of NMP22 test were significantly higher than those of urine cytology in bladder transitional cell carcinomas, especially with low grade and stage, it should be evaluated as a complemantary test to cytology rather than taking place of it as an assistant method to cystoscopy since it does not have sufficient specificity.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Mesane neoplazmları · Sitolojik teknikler · Karsinom

Abstract

This study has been prepared to evaluate the efficacy of NMP22 test in the followup of recurrent bladder transitional cell carcinoma and to compare it with urine cytology used to assist to cystoscopy. Urine samples voided prior to cystoscopic examination were collected from 94 patients who were in the follow-up program for superficial bladder cancer, and stabilized in the NMP22 urine collection kit. During the cystoscopic examination, the bladder cleaning sample for cytologic examination was taken by irrigating the bladder, and it was stabilized by the ethyl alcohol until cytopathologic analysis. Urines of those who had recurrent tumors had significantly higher NMP22 levels than those of those who did not have recurrent tumors (p<0.001). When reference value of 10 U/ml was used in NMP22 test, the sensitivity, specificity, positive predictive value and negative predictive value were 73.8%, 82.7%, 77.5% and 79.6%, respectively. The sensitivity and specificity of urine cytology were 52.4% and 90.4%, respectively. The sensitivity of NMP22 test was significantly higher than that of urine cytology in tumors with low grade and stage. Although the sensitivity and negative predictive value of NMP22 test were significantly higher than those of urine cytology in bladder transitional cell carcinomas, especially with low grade and stage, it should be evaluated as a complemantary test to cytology rather than taking place of it as an assistant method to cystoscopy since it does not have sufficient specificity.

Özet

Bu çalışmada nüks mesane transizyonel hücreli karsinomaların takibinde NMP22 testinin etkinliğini değerlendirmek ve bu amaçla sistoskopiye yardımcı olarak kullanılan idrar sitolojisi ile karşılaştırmak amaçlanmıştır. Yüzeyel mesane kanseri nedeniyle takip edilen 94 hastadan sistoskopik inceleme öncesi işenmiş idrar örneği alınarak, NMP22 idrar toplama kitinde stabilize edildi. Sitolojik inceleme için ise sistoskopik inceleme sırasında, mesane irrige edilerek mesane yıkama örneği alındı ve etil alkolle stabilize edilerek sitopatolojik analiz uygulandı. Nüks tümörü olanların olmayanlara göre idrar NMP22 düzeyinde anlamlı yükseklik olduğu gözlendi (p<0.001). NMP22 testinde 10 U/ml referans değeri olarak kullanıldığında sensitivite %73.8, spesifisite %82.7, pozitif öngörü değeri %77.5, negatif öngörü değeri ise %79.6 olarak bulunmuştur. İdrar sitolojisinin sensitivitesini %52.4, spesifisitesini ise %90.4 olarak bulduk. Düşük "grade" ve "stage" tümörlerde NMP22 testinin sensitivite oranlarının sitolojiden belirgin olarak yüksek olduğu görüldü. NMP22 testinin transizyonel hücreli mesane karsinomunda, özellikle düşük "grade" ve "stage" tümörlerde gösterdiği yüksek sensitivite ve negatif öngörü değerleri idrar sitolojisinden bariz üstün olmakla beraber, spesifisitedeki yetersizliğinden dolayı, sistoskopiye yardımcı bir metod olarak sitolojinin yerini almaktan ziyade, birbirini tamamlayan testler olarak değerlendirilmelidir

🔖

Cite This Article

SAĞNAK, L., ERSOY, H., KİPER, A., ESENGEN, S., TOPALOĞLU, H. (2007). The efficacy and the safety of the NMP22 test in the follow-up of urinary bladder transitional cell carcinoma after transurethral resection. Gülhane Tıp Dergisi, Cilt: 49 - Sayı: 1, 14–20. https://ajindex.com/articles/225547

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Edward M, Messing EM. Urothelial tumors of the urinary tract. In: Walsh R, Vaughan W (Eds) Campell's Urology. 8th ed. Vol.4. 2002: 2732-2784
  2. Lee R, Droller MJ. The natural history of bladder cancer. Implications for therapy. Urol Clin North Am 2000; 27: 1-13
  3. Oge O, Erdem E, Atsu N, et al. Proposal for changes in cystoscopic follow-up patients with low-grade pTa bladder tumor. Eur Urol 2000; 37: 271-274
  4. Ross JS, Cohen MB. Ancillary methods for the detection of recurrent urothelial neoplasia. Cancer 2000; 90: 75- 86
  5. Brown FM. Urine cytology. It is still the gold standart for screening? Urol Clin North Am 2000; 27: 25-37
  6. Konety BR, Getzenberg RH. Urine based markers of urological malignancy. J Urol 2001; 165: 600-611
  7. Koenig F, Jung K, Schnorr DL, et al. Urinary markers of malignancy. Clin Chim Acta 2000; 297: 191-205
  8. Sharma S, Zippe CD, Pandrangi L, et al. Exclusion criteria the specifity and positive predictive value of NMP22 and BTA stat. J Urol 1999; 162: 53-57
  9. Sawczuk IH, Lee B. The mechanism and clinical applications of the NMP22 tumor marker immunoassay:a review. Am Clin Lab 1999; 18: 24-26. 10.Stampfer DS, Carpinito GA, Rodrigez- Villanueva J, et al. Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder. J Urol 1998; 159: 394-398. 11.Morris SB, Shearer RJ, Gordon EM, Woodhouse CR. Superficial bladder cancer: timing of check cystoscopies in the first year. Br J Urol 1993; 72: 446- 448. 12.Meyhoff HH, Andersen JT, Klarskov P, et al. Flexible fiberoptic versus conventional cystourethroscopy in bladder tumor patients: a prospective study. Scand J Urol Nephrol 1988; 110: 237-240. 13.Koshikawa T, Leyk H, Schenck U. Difficulties in evaluating urinary specimens after local mitomycin therapy of bladder cancer. Diagn Cytopathol 1989; 5: 117-121. 14.Sarosdy MF, White RW, Soloway MS, et al. Results of a multicenter trial using the BTA test to monitor for and diagnose recurrent bladder cancer. J Urol 1995; 154: 379-383. 15.Sagerman PM, Saigo PE, Sheinfeld MD, et al. Enhanced detection of bladder cancer in cytology with Lewis X, M344 and 19A211 antigens. Acta Cytologica 1994; 38: 517-523. 16.Sanchez-Carbayo M, Urrutia M, Hernandez-Cerceno ML, Gonzales de Buitrago JM, Navajo JA. Cytokeratins (UBC and CYFRA 21-1) and nuclear matrix proteins (NMP22) as urine tumor markers in the diagnosis of bladder cancer. Med Clin (Barc) 2000; 114: 361-366. 17.Miyanaga N, Akaza H, Tsukamoto T, et al. Urinary nuclear matr